- Genome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy.
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher version
- BioMed Central Publisher's website
- Genome medicine Journal website
- Publication date:
- Pubs id:
- Local pid:
- Copyright holder:
- Nicol et al.
- Copyright date:
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic
If you are the owner of this record, you can report an update to it here: Report update to this record